HIV Drugs Market Size & Share, by Medication Class (Non-nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 162
  • Published Date: Sep 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

HIV Drugs Market size was valued at USD 34.61 billion in 2023 and is set to cross USD 74.73 billion by 2036, registering more than 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of HIV drugs is evaluated at USD 36.3 billion.

The growth of the HIV drugs market can be attributed to prevailing cases of acquired immune deficiency syndrome (AIDS). AIDS is caused by the transmission of a virus named human immunodeficiency virus (HIV). The data released by World Health Organisation states that in 2020, there were 1.5 million people who acquired HIV, and 680,000 people died from HIV-related causes. WHO also claims that in 2020 there were 37.7 million people who are living with AIDS. On the back of emerging cases of AIDS, the market is expected to grow during the forecast period. Furthermore, the governments are raising expenditure for the prevention and treatment of the disease. According to a report released by Joint United Nations Programme on HIV/AIDS (UNAIDS), the availability of international and domestic resources for the prevention and treatment of AIDS reached USD 21.5 million by the end of 2020. On account of the availability of a humongous budget for the treatment of AIDS, the market is projected to grow during the forecast period. Furthermore, the pro-active participation from all over the world to eliminate AIDS is remarkable. The World Health Organization promulgates 1st December as World AIDS Day to spread awareness about the prevention and treatment of the disease. The HIV drugs market is estimated to witness significant growth during the forecast period on account of the rising awareness amongst the people.


HIV Drug/Medicine Market
Get more information on this report: Request Free Sample PDF

HIV Drugs Sector: Growth Drivers and Challenges

Growth Drivers  

  • Surging Cases of Cancer Worldwide

  • Rising Initiatives by the Governments

Challenges 

  • Lack of Awareness Regarding the Treatment

HIV Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

CAGR

6.1%

Base Year Market Size (2023)

USD 34.61 billion

Forecast Year Market Size (2036)

USD 74.73 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

HIV Drugs Segmentation

The HIV drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, the hospital pharmacies sub-segment is anticipated to hold the largest share in the market during the forecast period on account of the growing number of HIV patients. A large number of HIV patients get admitted to hospitals is estimated to boost the market growth.  

Our in-depth analysis of the global market includes the following segments:

           Medication Class

  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Multi-Class Combination Drugs
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Protease Inhibitors (PIs)
  • Entry Inhibitors
  • HIV Integrase Strand Transfer Inhibitors

             Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

HIV Drugs Industry - Regional Synopsis

Regionally, the HIV drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America is likely to dominate majority revenue share by 2036, on the back of presence of an ultra-modern healthcare system. Furthermore, countries such as the USA are making people aware of the prevention and treatment of AIDS. The data released by the American Psychological Association states that 10th April is celebrated as National Youth HIV and AIDS Awareness Day. This event is celebrated to raise awareness amongst youth regarding the treatment of AIDS.

Furthermore, the market is expected to grow during the forecast period in the Asia Pacific region owing to a large number of patients in the region. According to the data released by UNAIDS in 2020, there were 5.8 million people living with HIV in the APAC region. On the back of the escalating number of HIV patients in the region, the HIV drugs market is projected to grow during the forecast period. Furthermore, the governments in the region are allotting a plethora of budgets for the prevention and treatment of HIV.

Research Nester
HIV-Drugs-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the HIV Drugs Landscape

    • Merck & Co., Inc.
      • Company Overview 
      • Business Strategy 
      • Key Product Offerings 
      • Financial Performance 
      • Key Performance Indicators 
      • Risk Analysis 
      • Recent Development 
      • Regional Presence 
      • SWOT Analysis 
    • Boehringer Ingelheim International GmbH
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc.
    • F. Hoffmann-La Roche Ltd.
    • Cipla Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Janssen Global Services, LLC
    • Mylan N.V.
    • AbbVie Inc. 

In the News

  • March 23, 2020: Gilead affirms that its supply chain is resilient even in the pandemic and does not see shortages of HIV treatment or prevention medicines in the future.

Author Credits:  Radhika Pawar


  • Report ID: 162
  • Published Date: Sep 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of HIV drugs is evaluated at USD 36.3 billion.

HIV Drugs Market size was valued at USD 34.61 billion in 2023 and is set to cross USD 74.73 billion by 2036, registering more than 6.1% CAGR during the forecast period i.e., between 2024-2036. The surging AIDS cases worldwide will impel the market growth.

North America is likely to dominate majority revenue share by 2036, on the back of presence of an ultra-modern healthcare system.

The major players in the market are F. Hoffmann-La Roche Ltd, Cipla Inc., Teva Pharmaceuticals Industries Ltd. and Janssen Global Services, LLC.
HIV Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample